September 2018 FDA Recall Synjardy by Boehringer Ingelheim Pharmaceuticals, Inc.
D-1217-2018 - Cross Contamination With Other Products

This Class II drug recall was voluntarily initiated by Boehringer Ingelheim Pharmaceuticals, Inc. on September 4, 2018 for the product Synjardy. The FDA reported the reason for recall as cross contamination with other products. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-1217-2018

Reason for Recall
Cross Contamination With Other Products:
Initiated
09-04-2018
Reported
10-03-2018
Quantity
998 180-count bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Boehringer Ingelheim Pharmaceuticals, Inc.
Synjardy (empagliflozin and metformin hydrochloride) Tablets. 5 mg/1000 mg. Rx only. 180-count bottle. Distributed by: Boehinger Ingelheim (BI) Pharmaceuticals, Inc. Ridgefield, CT 06877. Made in Germany. Marketed by: BI Pharmaceuticals, Inc. Ridgefield, CT 06877 and Eli Lilly and Company Indianapolis IN 46285 NDC 0597-0175-18

Batch or Lot Expiration Information

Lot# 603968 EXP 4/2019